Multicentric plasma cell variant of Castleman disease – A case reportMulticentric Plasma Cell Variant of Castleman Disease: A Case Report
DOI:
https://doi.org/10.21276/apalm.3359Keywords:
inguinal lymphadenopathy, iMCD, CD138, plasma cell variantAbstract
Castleman disease (CD) is a lymphoproliferative disorder with markedly different presentations and clinical courses. The manifestations of this rare disease depend on the distribution and pathologic subtype. The histological variants of CD include the hyaline vascular variant and the plasma cell variant, with the former constituting about 90% of cases. Clinically, the unicentric form of CD is associated with a better prognosis, while multicentric CD is linked to a long-term poor outcome with an increased risk of second malignancies. Histopathologic examination of the involved lymph nodes remains the mainstay of diagnosis due to the clinical heterogeneity of the disease.
We present the case of a 64-year-old male who was evaluated for bilateral inguinal lymphadenopathy, with a PET scan showing multiple hypermetabolic intra-abdominal lymph nodes. In view of a strong clinical suspicion of lymphoma, excision biopsy of the left inguinal lymph node was performed and sent for histopathological examination.
References
Nishimura MF, Nishimura Y, Nishikori A, Yoshino T, Sato Y. Historical and pathological overview of Castleman disease. J Clin Exp Hematop. 2022 Jun 28;62(2):60–72.
Saadallah MAH. Castleman’s disease: A rare case report and review of literature. Int J Surg Case Rep. 2022 Jun;95:107282.
Ehsan N, Zahra F. Castleman Disease. Treasure Island (FL): StatPearls Publishing; 2022.
Yasukawa M, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022 Jan 19;101(3):485–90.
Ekwere TA, Eziagu UB. Multicentric plasma-cell type Castleman disease masquerading as Hodgkin lymphoma: A case report. J Lab Physicians. 2020 Nov 23 [cited 2023 Nov 8];12(3):225–9.
El-Osta HE, Kurzrock R. Castleman’s disease: From basic mechanisms to molecular therapeutics. Oncologist. 2011 Mar 25;16(4):497–511.
Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am [Internet]. 2018 Feb 1 [cited 2022 Nov 24];32(1):11–21.
National Organization for Rare Disorders (NORD). Castleman disease.
Newlon JL, Couch ME, Brennan J. Castleman’s disease: Three case reports and a review of the literature. Ear Nose Throat J. 2007 Jul 1;86(7):414–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anitha Wilson, Elizabeth Joseph, Asha Peedikayil Punnoose, Minnu Elza Varghese, Ajmal T
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
